Although KPT-330 clinical trials have been very encouraging, non-covalent NEIs remain an interesting alternative for its possibly low-toxicity and broad-spectrum action as a CRM1-targeted anti-cancer therapy. This evidence concerns the gene XPO1 and cancer.